The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Exome Sequencing: Current and Future Perspectives
Open accessAbstract
The completion of a reference genome sequence for humans took more than 200 scientists more than a decade in a project that cost almost $3 billion to complete (International Human Genome Sequencing Consortium 2004). During the past decade the price of genome sequencing has plummeted, much of the work has become automated, and methods have improved. These advances mean complete genomes can be sequenced quickly and affordably. Human genome sequencing is a special case and enjoys much lower cost-per-gigabase than other species because of Illumina’s HiSeq X platform (Watson 2014). Sequencing can allow for the identification of genetic variants that affect heritable phenotypes, including important disease-causing mutations and natural variation that can be exploited to improve crops and livestock. Despite the significant improvement in sequencing technology, sequencing whole genomes to a depth sufficient to find variants that affect phenotypic expression is expensive compared with targeted sequencing. This review will focus on exome sequencing, a method that targets only a subset of the genome, often the protein coding portion, significantly reducing the sequencing space and subsequently the cost. Details of the method, available platforms, uses in humans and other species, and its benefits over whole-genome sequencing (WGS) will be discussed. The exome has been defined traditionally as the sequence encompassing all exons of protein coding genes in the genome and covers between 1 and 2% of the genome, depending on species. It also may be extended to target functional nonprotein coding elements (e.g., microRNA, long intergenic noncoding RNA, etc.) as well as specific candidate loci. There are two main categories of exome capture technology: solution-based and array-based. In solution-based, whole-exome sequencing (WES), DNA samples are fragmented and biotinylated oligonucleotide probes (baits) are used to selectively hybridize to target regions in the genome. Magnetic streptavidin beads are used to bind to the biotinylated probes, the nontargeted portion of the genome is washed away, and the polymerase chain reaction (PCR) is used to amplify the sample, enriching the sample for DNA from the target region. The sample is then sequenced before proceeding to bioinformatic analysis. Array-based methods are similar except that the probes are bound to a high-density microarray. The array-based method was the first to be used in exome capture (Albert et al. 2007), but it has largely been supplanted by solution-based methods, which require less input DNA and are consequently potentially more efficient; however, studies by Asan et al. (2011) and Bodi et al. (2013) found that NimbleGen’s Sequence Capture Array performed better than the solution-based alternatives in low GC content regions; had high sensitivity and read mapping rates; and single-nucleotide polymorphism (SNP) detection from these reads was more specific to the target region. This suggests that a niche may remain for the older technology. Array-based capture has been used successfully and accurately to identify rare and common variants and identify candidate genes for monogenic diseases in small cohorts (Ng et al. 2009); however, the array-based methods are less scalable owing to the limitation of the number of probes that can be accommodated on the array and additional equipment and time required to process the microarrays. There are several differences between the available platforms, which are constantly being updated and improved. The major providers of exome capture platforms are NimbleGen, Agilent, and Illumina, and each have different designs and strengths (summarized in Table 1). The discussion of the characteristics of each platform will focus on the solution-based human kits; the performance of kits for other species has not been subjected to the same level of comparison. UTR, untranslated region; miRNA, microRNA. As described in Clark et al. (2011), NimbleGen SeqCap EZ v2.0, Agilent SureSelect Human All Exon 50Mb, Illumina TruSeq Exome Enrichment. For NimbleGen SeqCap EZ v3.0, Agilent SureSelect V5, and Illumina TruSeq and Illumina Nextera original versions. Filtering for duplicates, multiple mappers, improper pairs, and off-target reads, data from Chilamakuri et al. (2014) . UTR, untranslated region; miRNA, microRNA. As described in Clark et al. (2011), NimbleGen SeqCap EZ v2.0, Agilent SureSelect Human All Exon 50Mb, Illumina TruSeq Exome Enrichment. For NimbleGen SeqCap EZ v3.0, Agilent SureSelect V5, and Illumina TruSeq and Illumina Nextera original versions. Filtering for duplicates, multiple mappers, improper pairs, and off-target reads, data from Chilamakuri et al. (2014) . NimbleGen’s SeqCap EZ Exome Library has the greatest bait density of any of the platforms and uses short (55−105 bp), overlapping baits to cover the target region (Clark et al. 2011). This approach has been found to be an efficient method for enrichment with the least amou
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Systematic Localization of Common Disease-Associated Variation in Regulatory DNA
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sandstrom, R., Qu, H., Brody, J., et al. (2012) · Science · doi:10.1126/science.1222794 · Cited by 3,716
An atlas of active enhancers across human cell types and tissues
The FANTOM Consortium, Andersson, R., Gebhard, C., Miguel-Escalada, I., Hoof, I., Bornholdt, J., Boyd, M., Chen, Y., Zhao, X., Schmidl, C., et al. (2014) · Nature · doi:10.1038/nature12787 · Cited by 2,550
Self-citationTargeted capture and massively parallel sequencing of 12 human exomes
Ng, S. B., Turner, E. H., Robertson, P. D., Flygare, S. D., Bigham, A. W., Lee, C., Shaffer, T., Wong, M., Bhattacharjee, A., Eichler, E. E., et al. (2009) · Nature · doi:10.1038/nature08250 · Cited by 2,030
Botstein, D., & Risch, N. (2003) · Nature Genetics · doi:10.1038/ng1090 · Cited by 1,503 · cited 2×
“Botstein, D., and N. Risch, 2003 Discovering genotypes underlying human phenotypes: past successes for Mendelian disease, future approaches for complex disease.”
BackgroundA physical, genetic and functional sequence assembly of the barley genome
The International Barley Genome Sequencing Consortium (2012) · Nature · doi:10.1038/nature11543 · Cited by 1,456
Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS
Johnson, J. O., Mandrioli, J., Benatar, M., Abramzon, Y., Van Deerlin, V. M., Trojanowski, J. Q., Gibbs, J. R., Brunetti, M., Gronka, S., Wuu, J., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.036 · Cited by 1,235
Large-scale discovery of novel genetic causes of developmental disorders
Study, T. D. D. D. (2015) · Nature · doi:10.1038/nature14135 · Cited by 1,124
Direct selection of human genomic loci by microarray hybridization
Albert, T. J., Molla, M. N., Muzny, D. M., Nazareth, L., Wheeler, D., Song, X., Richmond, T. A., Middle, C. M., Rodesch, M. J., Packard, C. J., et al. (2007) · Nature Methods · doi:10.1038/nmeth1111 · Cited by 681
Cited by
Next-Generation Sequencing Technology: Current Trends and Advancements
Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., Thakare, R. P., Banday, S., Mishra, A. K., Das, G., et al. (2023) · Biology · doi:10.3390/biology12070997 · Cited by 1,299
Past and Future Use of Wild Relatives in Crop Breeding
Dempewolf, H., Baute, G., Anderson, J., Kilian, B., Smith, C., & Guarino, L. (2017) · Crop Science · doi:10.2135/cropsci2016.10.0885 · Cited by 620
Paediatric genomics: diagnosing rare disease in children
Wright, C. F., FitzPatrick, D. R., & Firth, H. V. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.116 · Cited by 618
Defining the genetic, genomic, cellular, and diagnostic architectures of psychiatric disorders
Sullivan, P. F., & Geschwind, D. H. (2019) · Cell · doi:10.1016/j.cell.2019.01.015 · Cited by 452
“WES has identified 100 genes for ASD and an increased ‘‘burden’’ of rare, protein-altering genetic variation differing between cases and controls in SCZ and a few other disorders (Biesecker and Green, 2014; Warr et al. 2015).”
BackgroundFuentes‐Pardo, A. P., & Ruzzante, D. E. (2017) · Molecular Ecology · doi:10.1111/mec.14264 · Cited by 394
Metadata
- Authors
- Warr, A., Robert, C., Hume, D., Archibald, A., Deeb, N., & Watson, M.
- Venue
- G3 Genes|Genomes|Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08-01
- Volume
- 5
- Issue
- 8
- Pages
- 1543-1550
- ISSN
- 2160-1836 (ISSN-L)
- OpenAlex
- W2107752760
- Cited by
- 224
- References
- 10
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.